Clovis Oncology Inc: Diferență între versiuni
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Clovis Oncology, Inc. (www.clovisoncology.com)is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and other international markets. The Company operates through two geographic segments: U.S. and ex-U.S. The Company’s product Rubraca, is an oral small molecule inhibitor of poly [[ADP]]-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor which inhibits vascular endothelial growth factor receptors [[one]] through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3). Its other product includes FAP-2286, which is a clinical candidate under investigation as a peptide-targeted radionuclide therapy (PTRT). | Clovis Oncology, Inc. (www.clovisoncology.com)is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and other international markets. The Company operates through two geographic segments: U.S. and ex-U.S. The Company’s product Rubraca, is an oral small molecule inhibitor of poly [[ADP]]-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor which inhibits vascular endothelial growth factor receptors [[one]] through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors [[ONE|one]] through three (FGFR1-3). Its other product includes FAP-2286, which is a clinical candidate under investigation as a peptide-targeted radionuclide therapy (PTRT). | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||
Versiunea curentă din 25 noiembrie 2024 00:18
Pagina dedicata companiei Clovis Oncology Inc listata cu simbolul US.CLVS
Descriere companie[edit | ]
Clovis Oncology, Inc. (www.clovisoncology.com)is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and other international markets. The Company operates through two geographic segments: U.S. and ex-U.S. The Company’s product Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor which inhibits vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3). Its other product includes FAP-2286, which is a clinical candidate under investigation as a peptide-targeted radionuclide therapy (PTRT).
Grafic actiuni companie[edit | ]